## TEM: Tempus AI, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.7% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge. Caution: declining volume (49% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($65.97)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Recursion Pharmaceuticals registers 7.1 million shares for Tempus AI resale**
- Source: Investing.com | 20251201T050156 | Somewhat-Bullish | Relevance: 94%
- Recursion Pharmaceuticals Inc. has filed to register 7,088,742 shares of its Class A common stock for resale. These shares were issued to Tempus AI, Inc. as payment for annual license fees under an existing master agreement between the two companies. This move comes as Recursion Pharmaceuticals, currently trading at $4.37, faces cash burn challenges despite a strong liquidity position, following a Q3 2025 earnings report with an EPS of -$0.36 but a significant revenue miss of $5.18 million against an expected $16.95 million.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 3)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $85 | $80 | +6% |
| 2025-11-25 | BTIG | $105 | $96 | +9% |
| 2025-11-11 | Piper Sandler | $80 | $105 | -24% |
| 2025-11-11 | Morgan Stanley | $80 | $68 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-11-25 | BTIG | main | Buy |
| 2025-11-11 | Piper Sandler | main | Neutral |
| 2025-11-11 | Morgan Stanley | main | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- JPMORGAN CHASE & CO: 5.7% (+106.8%)
- BAILLIE GIFFORD & CO: 5.6% (-19.9%)
- Vanguard Group Inc: 5.5% (+22.1%)
- ARK Investment Manag: 4.2% (-3.3%)
- Blackrock Inc.: 3.9% (+62.8%)

### Key Risks

1. High beta (3.09) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Elevated short interest (13.7%): bears positioning against stock.
3. Near-term weakness: 8.8% below SMA50 despite long-term uptrend.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.49 indicates undervaluation relative to growth. Balance sheet: strong liquidity (3.3x). Revenue growth strong at 24% YoY. Analyst sentiment positive (4 raises, avg +19%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.2B |
| Beta | 1.00 |
| 52W Range | $31.36 - $104.32 |
| Short Interest | 13.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.49 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 2.8% to 1.7% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.3pp (needs >4.0% for momentum thesis). MRS_5 (-1.4%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.6% shows strong absolute momentum above own 20MA. MACD histogram positive (1.05), confirming momentum. RSI neutral at 48. Volume at 49% of 20MA suggests lack of conviction. OFD pattern: +MUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.73% (CS: 69) | Neutral |
| RSI_14 | 47.6 | Neutral |
| MACD Histogram | 1.05 | Bullish |
| vs SMA20 | 1.036x | Above |
| vs SMA50 | 0.912x | Below |
| vs SMA200 | 1.124x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $74.91
- **Stop Loss:** $65.97 (11.9% risk)
- **Target:** $83.85 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 106
- **Position Value:** $7,940.46
- **Portfolio %:** 7.94%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-24 (Est: $-0.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.18 | $-0.11 | +37.3% |
| 2025Q2 | $-0.25 | $-0.22 | +13.0% |
| 2025Q1 | $-0.27 | $-0.24 | +10.2% |
| 2024Q4 | $-0.15 | $-0.18 | -17.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*